We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AbbVie Cuts 2024 EPS Guidance to Include Acquisition Costs
Read MoreHide Full Article
In an SEC filing, AbbVie (ABBV - Free Report) has disclosed that it is lowering its previously issued guidance for 2024 adjusted earnings per share (EPS) by 88 cents due to in-process research and development (IPR&D) expenses incurred for acquisitions and collaborations during the fourth quarter.
The adjusted EPS guidance for full-year 2024 was lowered from $10.90-$10.94 to $10.02-$10.06 due to acquisition costs of $1.6 billion on a pre-tax basis. The Zacks Consensus Estimate for this metric is pegged at $10.96.
Including the acquired IPR&D and milestone expense, the fourth-quarter adjusted EPS guided range was lowered to $2.06-$2.10 from $2.94-$2.98. The Zacks Consensus Estimate for earnings is pegged at $2.99 per share.
The above projection does not impact AbbVie’s previously issued guidance for 2024 revenues, which are expected to be around $56 billion. Sales for the fourth quarter are expected to be roughly $14.8 billion.
ABBV is set to report fourth-quarter and full-year 2024 results on Jan. 31.
ABBV Stock Performance
In the past year, shares of AbbVie have gained about 12% against the industry’s 2% decline.
Image Source: Zacks Investment Research
What Led ABBV to Lower Its EPS Guidance?
During the fourth quarter, AbbVie completed the previously announced $1.4 billion acquisition of private biotech Aliada Therapeutics, which develops neuroscience drugs. With this new acquisition, AbbVie added Aliada’s lead pipeline drug, ALIA-1758, an anti-pyroglutamate amyloid beta antibody being evaluated in an early-stage study for Alzheimer's disease.
AbbVie also signed a collaboration and option-to-license agreement with EvolveImmune Therapeutics to develop next-generation cancer biotherapeutics and expanded its existing neuroscience partnership with Gedeon Richter. The closing of these agreements is likely to have triggered upfront cash payments from AbbVie’s end.
Bottom-line estimates for Castle Biosciences have improved from a loss of 8 cents per share to earnings of 34 cents for 2024 in the past 60 days. During the same timeframe, loss per share estimates for 2025 have narrowed from $1.88 to $1.84. In the past year, shares of Castle Biosciences have surged 34.3%.
CSTL’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 172.72%.
In the past 60 days, estimates for Puma Biotechnology’s 2024 earnings per share have risen from 43 cents to 49 cents. Estimates for 2025 EPS have increased from 42 cents to 53 cents during the same timeframe. In the past year, Puma’s shares have lost 26.4%.
PBYI’s earnings beat estimates in three of the trailing four quarters and missed the mark on one occasion, delivering an average surprise of 32.78%.
In the past 60 days, estimates for CytomX Therapeutics’ 2024 loss per share have narrowed from 29 cents to 5 cents. Estimates for 2025 loss per share have narrowed from 56 cents to 35 cents during the same timeframe. CTMX’s shares have lost 28.3% in the past year.
CytomX’s earnings beat estimates in two of the trailing four quarters and missed the mark in the other two, delivering an average surprise of 115.70%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
AbbVie Cuts 2024 EPS Guidance to Include Acquisition Costs
In an SEC filing, AbbVie (ABBV - Free Report) has disclosed that it is lowering its previously issued guidance for 2024 adjusted earnings per share (EPS) by 88 cents due to in-process research and development (IPR&D) expenses incurred for acquisitions and collaborations during the fourth quarter.
The adjusted EPS guidance for full-year 2024 was lowered from $10.90-$10.94 to $10.02-$10.06 due to acquisition costs of $1.6 billion on a pre-tax basis. The Zacks Consensus Estimate for this metric is pegged at $10.96.
Including the acquired IPR&D and milestone expense, the fourth-quarter adjusted EPS guided range was lowered to $2.06-$2.10 from $2.94-$2.98. The Zacks Consensus Estimate for earnings is pegged at $2.99 per share.
The above projection does not impact AbbVie’s previously issued guidance for 2024 revenues, which are expected to be around $56 billion. Sales for the fourth quarter are expected to be roughly $14.8 billion.
ABBV is set to report fourth-quarter and full-year 2024 results on Jan. 31.
ABBV Stock Performance
In the past year, shares of AbbVie have gained about 12% against the industry’s 2% decline.
Image Source: Zacks Investment Research
What Led ABBV to Lower Its EPS Guidance?
During the fourth quarter, AbbVie completed the previously announced $1.4 billion acquisition of private biotech Aliada Therapeutics, which develops neuroscience drugs. With this new acquisition, AbbVie added Aliada’s lead pipeline drug, ALIA-1758, an anti-pyroglutamate amyloid beta antibody being evaluated in an early-stage study for Alzheimer's disease.
AbbVie also signed a collaboration and option-to-license agreement with EvolveImmune Therapeutics to develop next-generation cancer biotherapeutics and expanded its existing neuroscience partnership with Gedeon Richter. The closing of these agreements is likely to have triggered upfront cash payments from AbbVie’s end.
ABBV’s Zacks Rank
AbbVie currently carries a Zacks Rank #3 (Hold).
AbbVie Inc. Price
AbbVie Inc. price | AbbVie Inc. Quote
Key Picks Among Biotech Stocks
Some better-ranked stocks from the sector are Castle Biosciences (CSTL - Free Report) , Puma Biotechnology (PBYI - Free Report) and Spero Therapeutics (SPRO - Free Report) , each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Bottom-line estimates for Castle Biosciences have improved from a loss of 8 cents per share to earnings of 34 cents for 2024 in the past 60 days. During the same timeframe, loss per share estimates for 2025 have narrowed from $1.88 to $1.84. In the past year, shares of Castle Biosciences have surged 34.3%.
CSTL’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 172.72%.
In the past 60 days, estimates for Puma Biotechnology’s 2024 earnings per share have risen from 43 cents to 49 cents. Estimates for 2025 EPS have increased from 42 cents to 53 cents during the same timeframe. In the past year, Puma’s shares have lost 26.4%.
PBYI’s earnings beat estimates in three of the trailing four quarters and missed the mark on one occasion, delivering an average surprise of 32.78%.
In the past 60 days, estimates for CytomX Therapeutics’ 2024 loss per share have narrowed from 29 cents to 5 cents. Estimates for 2025 loss per share have narrowed from 56 cents to 35 cents during the same timeframe. CTMX’s shares have lost 28.3% in the past year.
CytomX’s earnings beat estimates in two of the trailing four quarters and missed the mark in the other two, delivering an average surprise of 115.70%.